These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 11458552)

  • 1. Femara approved as first-line breast cancer therapy.
    FDA Consum; 2001; 35(3):5. PubMed ID: 11458552
    [No Abstract]   [Full Text] [Related]  

  • 2. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
    Cohen MH; Johnson JR; Li N; Chen G; Pazdur R
    Clin Cancer Res; 2002 Mar; 8(3):665-9. PubMed ID: 11895893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Letrozole as adjuvant therapy for postmenopausal women with early breast cancer.
    Russell CA
    Manag Care Interface; 2007 Sep; 20(9):30-1, 36. PubMed ID: 18161388
    [No Abstract]   [Full Text] [Related]  

  • 4. New breast cancer drug.
    Brink S
    US News World Rep; 2001 Dec; 131(26):52. PubMed ID: 11793594
    [No Abstract]   [Full Text] [Related]  

  • 5. Breast cancer drug shows promise for some survivors.
    Levenson D
    Rep Med Guidel Outcomes Res; 2003 Oct; 14(21):7-9. PubMed ID: 14628765
    [No Abstract]   [Full Text] [Related]  

  • 6. Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen.
    Mann BS; Johnson JR; Kelly R; Sridhara R; Williams G; Pazdur R
    Clin Cancer Res; 2005 Aug; 11(16):5671-7. PubMed ID: 16115902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast cancer's 'new era'.
    Noonan D
    Newsweek; 2003 Oct; 142(16):67-8. PubMed ID: 16124190
    [No Abstract]   [Full Text] [Related]  

  • 8. Dual-action drug approved for use in advanced breast cancer.
    McBride D
    ONS Connect; 2007 Jun; 22(6):19. PubMed ID: 17598617
    [No Abstract]   [Full Text] [Related]  

  • 9. New drugs reduce risk of death from breast cancer.
    Health News; 2004 Oct; 10(10):4. PubMed ID: 15584111
    [No Abstract]   [Full Text] [Related]  

  • 10. Long-term insurance for breast cancer survivors.
    Johns Hopkins Med Lett Health After 50; 2004 Apr; 16(2):3, 7. PubMed ID: 15088564
    [No Abstract]   [Full Text] [Related]  

  • 11. [Superiority of letrozole compared with tamoxifen as first line therapy of postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group].
    Illiger HJ
    Strahlenther Onkol; 2002 Feb; 178(2):111-3. PubMed ID: 11942036
    [No Abstract]   [Full Text] [Related]  

  • 12. Drugs may improve long-term outcomes after breast cancer.
    Mayo Clin Health Lett; 2004 Mar; 22(3):4. PubMed ID: 15000065
    [No Abstract]   [Full Text] [Related]  

  • 13. Promising results for Arimidex and Femara.
    Expert Rev Anticancer Ther; 2001 Dec; 1(4):508-9. PubMed ID: 12113080
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical research. No lifeline for proposed breast cancer prevention trial.
    Kaiser J
    Science; 2007 Jun; 316(5832):1679. PubMed ID: 17588904
    [No Abstract]   [Full Text] [Related]  

  • 15. Superiority of letrozole to tamoxifen in the first-line treatment of advanced breast cancer: evidence from metastatic subgroups and a test of functional ability.
    Mouridsen H; Sun Y; Gershanovich M; Perez-Carrion R; Becquart D; Chaudri-Ross HA; Lang R
    Oncologist; 2004; 9(5):489-96. PubMed ID: 15477633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Focus on anastrozole and breast cancer.
    Mokbel K
    Curr Med Res Opin; 2003; 19(8):683-8. PubMed ID: 14687437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Letrozole Breast Cancer Trial: clinical implications and remaining questions.
    Chen WY; Manson JE
    Womens Health Issues; 2004; 14(1):7-10. PubMed ID: 15001182
    [No Abstract]   [Full Text] [Related]  

  • 18. Superiority of letrozole over tamoxifen in the first-line treatment of metastatic breast cancer patients with normal serum Her-2/neu levels: question of tamoxifen resistance.
    Altundag K; Altundag O
    J Clin Oncol; 2003 Dec; 21(24):4656; author reply 4657. PubMed ID: 14673060
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy of first-line letrozole versus tamoxifen as a function of age in postmenopausal women with advanced breast cancer.
    Mouridsen H; Chaudri-Ross HA
    Oncologist; 2004; 9(5):497-506. PubMed ID: 15477634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer research. Budget pressure puts high-profile study in doubt.
    Marshall E
    Science; 2007 Mar; 315(5818):1477. PubMed ID: 17363634
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.